asco abstract rais question answer lower pt
gener forma cash includ mileston payment
announc
earli efficaci data appear underwhelm expect
toxic increas higher dose abstract
conjug pdc develop collabor
rate achiev modest orr efficaci evalu
advanc cancer patient three median prior rx note
dose escal natur datawith dose escal continu
despit median molar ratio mask total
auctau ratio free mmae total
alreadi shown
trae anemia neutropenia rate would expect trae
rate increas dose escal continu therefor
question well toler agent would dose requir
meaning respons lower probabl
approv prior
abstract abstract result rais
addit question full dose escal data set
elicit five respons breast cancer bc patient orr
much lower orr seen
kg note howev unclear
bc pt receiv dose patient origin
dose escal cohort receiv ocular prophylaxi
dose refin phase led longer treatment
durat thu improv efficaci regard point
trae rate monotherapi
tick upward prior patient treat
longer month show trae rate
similar trae rate histor seen monotherapi
agent trae yervoy
kg also increas lower probabl
approv prior
await color abstract dose
larger yervoy use
achiev trae rate
vs trae rate yervoy reduct
trae rate seen use
dose regimen find encourag howev efficaci
data present seemingli lower percentag
remain mask system circul seen
overal decidedli mix bag given open question
bright spot low
trae rate dose regimen
believ origin probodi platform hypothesi may remain
intact would like convinc proof seen asco
abstract accordingli lower price target
previou per share remain confid cytomx
collabor balanc sheet strength feel stock may
range-bound evid pipelin promis forthcom
definit distribut analyst rate analyst certif disclosur pleas refer page report
reiter buy lower pt util probabl approv
appli discount rate effect tax rate translat price per share
assum share outstand roughli cash cash equival market secur
risk includ limit emerg unexpect side effect
futur clinic data inabl show competit efficaci
safeti clinic trial vs exist checkpoint inhibitor delay obtain regulatori approv
lower-than-project market penetr rate clinic failur pipelin candid
impact clinic develop compani oper on-going pandem
thousand except per share data
compani report wainwright co estim
revenu relat parties- total expensescost sales- research related- wholli own partner gener intern gener sell marketing- total gain loss income/expenseinterest incom incom expens total invest incom loss benefit provis incom benefit provis incom net incom net loss per share net loss per share weight averag number share outstand weight averag number share outstand inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc ctmx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
robert burn raghuram selvaraju ph certifi view express report accur reflect
person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur cytomx
therapeut inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
